TY - JOUR
T1 - Protocol for quantitative and qualitative analyses of the in vitro aggregation of synthetic β-amyloid
T2 - A method applicable to the identification of substances that may have therapeutic efficacy for Alzheimer's disease
AU - Chang, Pei Teh
AU - Su, Yeu
N1 - Funding Information:
We like to thank Dr. Andrew C-Y Shum of The Department and Institute of Pharmacology, National Yang-Ming University for critically reading the manuscript. This work was supported by grants NSC87-2314-B-010-056 and NSC88-2314-B-010-118 from the National Science Council of R.O.C.
PY - 2000
Y1 - 2000
N2 - Biochemical studies of β-amyloid (Aβ) aggregation have been hampered by the lack of a simple method to examine simultaneously the extent of aggregation and the structural nature of the aggregates. Consequently, often only the extent of aggregation is analyzed and reported. This means that there is often no knowledge of whether the aggregates consist of fibrils, a structure crucial for their neurotoxicity. Here we describe the development of a protocol for quantitatively and qualitatively evaluating the in vitro aggregation of synthetic Aβ. Specifically, a fluorescein derivatized Aβ1-42 peptide (FITC-Aβ1-42) was used as the aggregation material. We found that the fluorescent Aβ peptide aggregated as efficiently as the native ones and the extent of their aggregation could be determined accurately by fluorescence spectrophotometry. Significantly, our approach is also qualitative because it allows a direct structural examination of Aβ fibrils by fluorescence microscopy. In addition, this protocol can also be applied to the identification of substance(s) capable of inhibiting Aβ aggregation and further the assessment of the nature of such inhibition. (C) 2000 Elsevier Science B.V.
AB - Biochemical studies of β-amyloid (Aβ) aggregation have been hampered by the lack of a simple method to examine simultaneously the extent of aggregation and the structural nature of the aggregates. Consequently, often only the extent of aggregation is analyzed and reported. This means that there is often no knowledge of whether the aggregates consist of fibrils, a structure crucial for their neurotoxicity. Here we describe the development of a protocol for quantitatively and qualitatively evaluating the in vitro aggregation of synthetic Aβ. Specifically, a fluorescein derivatized Aβ1-42 peptide (FITC-Aβ1-42) was used as the aggregation material. We found that the fluorescent Aβ peptide aggregated as efficiently as the native ones and the extent of their aggregation could be determined accurately by fluorescence spectrophotometry. Significantly, our approach is also qualitative because it allows a direct structural examination of Aβ fibrils by fluorescence microscopy. In addition, this protocol can also be applied to the identification of substance(s) capable of inhibiting Aβ aggregation and further the assessment of the nature of such inhibition. (C) 2000 Elsevier Science B.V.
KW - Aggregation
KW - Aggregation inhibitor
KW - Fluorescein isothiocyanate
KW - β-amyloid
UR - http://www.scopus.com/inward/record.url?scp=0033731532&partnerID=8YFLogxK
U2 - 10.1016/S1385-299X(00)00031-3
DO - 10.1016/S1385-299X(00)00031-3
M3 - Article
C2 - 11086258
AN - SCOPUS:0033731532
SN - 1385-299X
VL - 6
SP - 6
EP - 12
JO - Brain Research Protocols
JF - Brain Research Protocols
IS - 1-2
ER -